Profusa has launched its Healthcare Research version of the Lumee tissue oxygen system, leading to a significant stock rally of 20.30%. This new focus targets a rapidly growing CRO market, expected to facilitate immediate revenue generation and improve drug development efficiency, suggesting strong future prospects for the company.
Profusa restructured its debt, raising conversion floor price to stabilize finances. Elimination of cash and equity payments provides improved cash flow breathing room. PFSA shares surged 73% but remain far from their 52-week high of $2.40. The company faces a Nasdaq non-compliance notice amid high volatility. Speculative buying increased after the announcement, indicating investor confidence.